25/06/2025
📒 Myeloproliferative neoplasms (MPNs) are a group of blood cancers that occur when the body produces too many🩸cells in an uncontrolled way. In more than 70% of cases, this is caused by a genetic mutation 🧬 known as JAK2 V617F, which sends abnormal signals that activate certain receptors on blood cells. One of the most important of these is the thrombopoietin receptor (TpoR), which regulates the production of platelets and the renewal of blood stem cells.
📢 In a new study published in Blood, Papadopoulos and colleagues explored how the JAK2 V617F mutation induces MPNs through both TpoR-dependent and TpoR-independent pathways.
Their research helps us better understand the pathophysiology of MPNs, clarifies the unique role of TpoR compared to other receptors, and supports the idea that blocking abnormal TpoR activation could be a promising direction for future therapies.
Reference of the paper:
Delineating Mpl-dependent and -independent phenotypes of Jak2 V617F- positive MPNs in vivo
Papadopoulos N, Nédélec A, Rahmani Y, Ryou H, Defour JP, Rittscher J, Royston D, Constantinescu SN
Blood (2025) blood.2024026711